Business Description
Abeona Therapeutics Inc
NAICS : 325413
SIC : 2834
ISIN : US00289Y1073
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.67 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -16.93 | |||||
Beneish M-Score | 4.39 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -60.7 | |||||
3-Year EBITDA Growth Rate | 51 | |||||
3-Year EPS without NRI Growth Rate | 47.3 | |||||
3-Year FCF Growth Rate | 43.7 | |||||
3-Year Book Growth Rate | -72.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 16.76 | |||||
9-Day RSI | 20.6 | |||||
14-Day RSI | 25.86 | |||||
6-1 Month Momentum % | 90.71 | |||||
12-1 Month Momentum % | 142.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.15 | |||||
Quick Ratio | 4.15 | |||||
Cash Ratio | 3.89 | |||||
Days Sales Outstanding | 365 | |||||
Days Payable | 572.86 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -90.4 | |||||
Shareholder Yield % | -3.81 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 54.14 | |||||
Operating Margin % | -1377.14 | |||||
Net Margin % | -1548.23 | |||||
FCF Margin % | -1071.56 | |||||
ROE % | -295.43 | |||||
ROA % | -89.95 | |||||
ROIC % | -356.96 | |||||
ROC (Joel Greenblatt) % | -565.4 | |||||
ROCE % | -105.55 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.39 | |||||
PB Ratio | 7.42 | |||||
Price-to-Tangible-Book | 7.4 | |||||
EV-to-EBIT | -1.24 | |||||
EV-to-EBITDA | -1.32 | |||||
EV-to-Revenue | 19.06 | |||||
EV-to-Forward-Revenue | 20.51 | |||||
EV-to-FCF | -1.79 | |||||
Price-to-Net-Current-Asset-Value | 16.74 | |||||
Price-to-Net-Cash | 39.75 | |||||
Earnings Yield (Greenblatt) % | -80.65 | |||||
FCF Yield % | -32.89 |